Kakinada’s Penicillin-G Facility: A Leading Pharma Manufacturing Hub

Overview of the Kakinada Facility

The Penicillin-G (Pen-G) facility situated in the Special Economic Zone (SEZ) at Kakinada, Andhra Pradesh, is an impressive manufacturing asset in the pharmaceutical industry. With state-of-the-art technology and significant production capacities, this facility plays a crucial role in meeting both domestic and international healthcare needs.

Key Production Capacities

• Penicillin-G Production:
• Capacity: 15,000 tonnes per annum
• This robust output underlines the facility’s capability to support the increasing demand for antibiotics.
• Glucose Production:
• Capacity: 1.8 lakh tonnes annually
• The facility also specializes in glucose production, essential for various pharmaceutical applications.
• 6-Amino Penicillanic Acid:
• Capacity: 3,600 tonnes annually
• This compound serves as a key intermediate in penicillin production, contributing to the overall operational efficiency of the facility.

Importance of the Facility

The Kakinada facility stands out not only for its production capacities but also for its strategic importance within the pharmaceutical supply chain. By operating in a SEZ, the facility benefits from enhanced regulatory environments and operational incentives, positioning it as a competitive player in the global market.

Conclusion

The Penicillin-G facility at Kakinada is a landmark achievement in pharmaceutical manufacturing. As it continues to produce essential antibiotics and related compounds, its contributions significantly impact the industry's ability to deliver healthcare solutions. This facility not only affirms India's growing status as a pharmaceutical hub but also highlights the potential for advancements in drug production technology.